Baseline markers such as GRP78/BiP and the XBP1 splicing ratio estimate how much a tumor is already relying on chaperone buffering or IRE1 signaling; this helps choose which arm to target (PERK/IRE1/ATF6, ROS amplification, Ca2+ handling, or proteostasis). The gene discussed is EIF2AK3; the disease is neoplasm.